Skip to main content

21 Code of Federal Regulations Parts 211 Subpart A-General Provisions

21 Code of Federal Regulations
Parts 211
Subpart A-General Provisions
211.1 Scope

(a) The regulations in this part contain the minimum current good manufacturing practice for
preparation of drug products for administration to humans or animals.

(b) The current good manufacturing practice regulations in this chapter, as they pertain to drug
products, and in parts 600 through 680 of this chapter, as they pertain to biological products for
human use, shall be considered to supplement, not supersede, the regulations in this part unless the regulations explicitly provide otherwise. In the event it is impossible to comply with applicable regulations both in this part and in other parts of this chapter or in parts 600 through 680 of this chapter, the regulation specifically applicable to the drug product in question shall supersede the regulation in this part.

(c) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this part shall not be enforced for OTC drug products if the products and all their ingredients are ordinarily marketed and consumed as human foods, and which products may also fall within the legal definition of drugs by virtue of their intended use. Therefore, until further notice, regulations under part 110 of this chapter, and where applicable, parts 113 to 129 of this chapter, shall be applied in determining whether these OTC drug products that are also foods are manufactured, processed, packed, or held under current good manufacturing practice.

§ 211.3 Definitions.


The definitions set forth in § 210.3 of this chapter apply in this part.

Comments

Post a Comment

Popular posts from this blog

DATA INTEGRITY (ALCOA ++)

 INTRODUCTION   The purpose of this guidance is to clarify the role of data integrity in current good manufacturing  practice (CGMP) for drugs, as required in 21 CFR parts 210, 211, and 212. Part 210 covers  Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of  Drugs; General; part 211 covers Current Good Manufacturing Practice for Finished  Pharmaceuticals; and part 212 covers Current Good Manufacturing Practice for Positron  Emission Tomography Drugs. This guidance provides the Agency’s current thinking on the creation and handling of data in accordance with CGMP requirements. FDA expects that data be reliable and accurate (see the “Background” section). CGMP  regulations and guidance allow for flexible and risk-based strategies to prevent and detect data  integrity issues. Firms should implement meaningful and effective strategies to manage their data  integrity risks based upon their proc...
Post a Comment
Read more

PERMITTED DAILY EXPOSURE (PDE)

PERMITTED DAILY EXPOSURE (PDE) or ACCEPTANCE DAILY EXPOSURE Introduction During the manufacture of medicinal products accidental cross contamination can result from the uncontrolled release of dust, gases, vapours, aerosols, genetic material or organisms from active substances, other starting materials, and other products being processed concurrently, as well as from residues on equipment, and from operators ’ clothing. Due to the perceived risk, certain classes of medicinal product have previously been required to be manufactured in dedicated or segregated self contained facilities including, “certain antibiotics, certain hormones, certain cytotoxics and certain highly active drugs”. Until now no official guidance is available in order to assist manufacturers to differentiate between individual products within these specified classes. METHODS FOR ESTABLISHING EXPOSURE LIMITS The Gaylor-Kodell method of risk assessment (Gaylor, D. W. and Kodell, R. L.: Linea...
Post a Comment
Read more

US-FDA GUIDELINES (21 CFR)

21 Code of Federal Regulations Parts 210 and 211 Part 210 - CURRENT GOOD MANUFACTURING PRACTICE IN MANUFACTURING, PROCESSING, PACKING, OR HOLDING OF DRUGS; GENERAL Part 211 - CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS Part 210 - CURRENT GOOD MANUFACTURING PRACTICE IN MANUFACTURING, PROCESSING, PACKING, OR HOLDING OF DRUGS; GENERAL 210.1 Status of current good manufacturing practice regulations. 210.2 Applicability of current good manufacturing practice regulations. 210.3 Definitions. AUTHORITY: Secs. 201, 501, 502, 505, 506, 507, 512, 701, 704 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 351, 352, 355, 356, 357, 360b, 371, 374). SOURCE: 43 FR 45076, Sept. 29, 1978, unless otherwise noted. PART 211 - CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS Subpart A - General Provisions 211.1 Scope 211.3 Definitions Subpart B - Organization and Personnel 211.22 Responsibiliti...
Post a Comment
Read more